COMBINED HER2 AND MESO DUAL-TARGET CAR-T VECTOR, CONSTRUCTION METHOD THEREFOR AND APPLICATION THEREOF IN CANCER - SHANGHAI INST OF BIOLOGICAL PRODUCTS CO LTD

Title:

COMBINED HER2 AND MESO DUAL-TARGET CAR-T VECTOR, CONSTRUCTION METHOD THEREFOR AND APPLICATION THEREOF IN CANCER

Document Type and Number:

WIPO Patent Application WO/2023/016524

Kind Code:

A1

Abstract:

A combined HER2 and MESO dual-target CAR-T vector, a construction method therefor and an application thereof in cancer are provided; specifically, a bispecific chimeric antigen receptor (CAR) containing HER2 scFv and MESO scFv, a 4-1BB co-stimulatory domain, and a CD3 activation domain is provided. The bispecific CAR-T cell has a significant killing effect on HER2-positive target cells and MESO-positive target cells and can improve on the tumor-killing effect of T cells; the cytokines produced have a super-additive effect, and compared with a single-target CAR-T, can better clear tumor cells, alleviate antigen escape caused by tumor heterogeneity, and further strengthen the ability of CAR-T cells to kill tumors.

More Like This:

JP7313497	Enzyme-mediated depletion methods for adenosine and/or methylthioadenosine
JP2004175665	PROTEIN HOLLOW NANOPARTICLE AND DRUG USING THE SAME
JP2520464	INDUSTRIAL APPLICABILITY: Monochrome-nal antibody that neutralizes HIV-1.

Inventors:

JIANG FENGTING (CN)
LUO JIAN (CN)
ZHENG MEI (CN)
DING YAHONG (CN)
XIONG FEIFEI (CN)
LIU XUEYIN (CN)
ZHOU XU (CN)

Application Number:

PCT/CN2022/111866

Publication Date:

February 16, 2023

Filing Date:

August 11, 2022

Export Citation:

Click for automatic bibliography generation Help

Assignee:

SHANGHAI INST OF BIOLOGICAL PRODUCTS CO LTD (CN)

International Classes:

C07K19/00; C12N5/10; C12N15/62; C12N15/867

Domestic Patent References:

WO2019126724A1	2019-06-27
WO2021087183A1	2021-05-06

Foreign References:

CN113651893A	2021-11-16
CN112778427A	2021-05-11
CN109575143A	2019-04-05
CN106456784A	2017-02-22
CN111511911A	2020-08-07
CN113227379A	2021-08-06

Other References:

YANG, PEIWEI ET AL.: "Enhanced Safety and Antitumor Efficacy of Switchable Dual Chimeric Antigen Receptor-Engineered T Cells against Solid Tumors through a Synthetic Bifunctional PD-L1-Blocking Peptide", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 142, 23 September 2020 (2020-09-23), pages 18874 - 18885, XP055798614, DOI: 10.1021/jacs.0c08538

Attorney, Agent or Firm:

XU&PARTNERS, LLC. (CN)

Download PDF:

View/Download PDF PDF Help

Previous Patent: COOPERATIVE PULSE GENERATION APPARATUS, DEVICE AND GENERATION METHOD

Next Patent: COMPOUND AS ATR KINASE INHIBITOR